puccini: early metabolic response predicts survival in patients with mbc receiving cdk4/6 inhibitors
Published 1 year ago • 119 plays • Length 4:17Download video MP4
Download video MP3
Similar videos
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
1:12
remaining questions on the use of frontline cdk4/6 inhibitors endocrine therapy
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
1:08
overcoming resistance to cdk4/6 inhibitors in er breast cancer via ctdna
-
5:33
mammatyper | innovation in breast cancer diagnosis
-
33:42
head and neck cancer and immunotherapy with dr. nabil f. saba
-
10:39
cell cycle regulation, part 5: cdk inhibitors
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
1:54
cell cycle inhibitors - cdk4/6 inhibitors
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
6:30
sabcs 2023: a look into new research for inflammatory breast cancer
-
2:27
understanding abemaciclib: a new cdk4/6 inhibitor
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
8:30
advances in early-stage breast cancer treatment: a recap of the natalee trial
-
1:12
monarche: adjuvant abemaciclib in hr breast cancer
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
2:22
analysis of assay used in impassion130 to guide treatmeant of metastatic and advanced breast can...